Complement activation in astrocytomas: deposition of C4d and patient outcome

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Mäkelä, Katri ^a,c   Helén, Pauli ^b   Haapasalo, Hannu ^a,b   Paavonen, Timo ^a,b  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Astrocytoma; C4d; Complement; Glioblastoma; Immunohistochemistry; Inflammation; Survival

Indexed keywords

BIOLOGICAL MARKER; CD34 ANTIGEN; COMPLEMENT COMPONENT C4D;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHILD; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DETERIORATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MORPHOMETRICS; PATHOPHYSIOLOGY; PILOCYTIC ASTROCYTOMA; QUANTITATIVE ANALYSIS; SCHOOL CHILD; TISSUE MICROARRAY; TUMOR MICROENVIRONMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ASTROCYTOMA; BRAIN NEOPLASMS; CHI-SQUARE DISTRIBUTION; CHILD; COMPLEMENT ACTIVATION; COMPLEMENT C4B; DISEASE PROGRESSION; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; PEPTIDE FRAGMENTS; PROGNOSIS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84870701583     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-565     Document Type: Article

References (18)

1. Cavenee WK, Louis DN, Ohgaki H, Wiestler OD. World health organization classification of tumours of the central nervous system 2007, France, Lyon.
2. Trouw LA, Daha MR. Role of complement in innate immunity and host defense. Immunol Lett 2011, 138:35-37. 10.1016/j.imlet.2011.02.014, 21333684.
3. Baldwin WM, Kasper EK, Zachary AA, Wasowska BA, Rodriguez ER. Beyond C4d: other complement-related diagnostic approaches to antibody-mediated rejection. Am J Transplant 2004, 4:311-318. 10.1111/j.1600-6143.2004.00348.x, 14961982.
4. Feucht H. Complement C4d in graft capillaries - the missing link in the recognition of humoral alloreactivity. Am J Transplant 2003, 3:646-652. 10.1034/j.1600-6143.2003.00171.x, 12780555.
5. Murata K, Baldwin WM. Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando) 2009, 23:139-150.
6. Lucas SD, Karlsson-Parra A, Nilsson B, Grimelius L, Akerström G, Rastad J, Juhlin C. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol 1996, 27:1329-1335. 10.1016/S0046-8177(96)90346-9, 8958307.
7. Bu X, Zheng Z, Wang C, Yu Y. Significance of C4d deposition in the follicular lymphoma and MALT lymphoma and their relationship with follicular dendritic cells. Pathol Res Pract 2007, 203:163-167. 10.1016/j.prp.2006.11.004, 17307308.
8. Yin W, Ghebrehiwet B, Weksler B, Peerschke EI. Classical pathway complement activation on human endothelial cells. Mol Immunol 2007, 44:2228-2234. 10.1016/j.molimm.2006.11.012, 1865514, 17173972.
9. Siitonen S, Haapasalo H, Rantala I, Helin H, Isola J. Comparison of different immunohistochemical methods in the assessment of angiogenesis: lack of prognosis value in a group of 77 selected node-negative breast carcinomas. Mod Pathol 1995, 8:745-752.
10. Gousias K, Markou M, Arzoglou V, Voulgaris S, Vartholomatos G, Kostoula A, Voulgari P, Polyzoidis K, Kyritsis AP. Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. J Neuroimmunol 2010, 226:136-142. 10.1016/j.jneuroim.2010.05.027, 20605226.
11. Shinoura N, Heffelfinger SC, Miller M, Shamraj OI, Miura NH, Larson JJ, DeTribolet N, Warnick RE, Tew JJ, Menon AG. RNA expression of complement regulatory proteins in human brain tumors. Cancer Lett 1994, 86:143-149. 10.1016/0304-3835(94)90072-8, 7526972.
12. Murray KP, Mathure S, Kaul R, Khan S, Carson LF, Twiggs LB, Martens MG, Kaul A. Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecol Oncol 2000, 76:176-182. 10.1006/gyno.1999.5614, 10637067.
13. Mäenpää A, Junnikkala S, Hakulinen J, Timonen T, Meri S. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol 1996, 148:1139-1152. 1861510, 8644856.
14. Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 2000, 164:6075-6081.
15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
16. Walport MJ. Complement. Second of two parts. N Engl J Med 2001, 344:1140-1144. 10.1056/NEJM200104123441506, 11297706.
17. Hussain SP, Harris C. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007, 121:2373-2380. 10.1002/ijc.23173, 17893866.
18. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899. 10.1016/j.cell.2010.01.025, 2866629, 20303878.